Moderna, Inc.

Moderna, Inc.'s next confirmed earnings release is scheduled for November 6, 2026.

As of June 30, 2026, Moderna, Inc. has 399.00M shares outstanding.

As of June 30, 2026, Moderna, Inc. maintains a current ratio of 2.29, meaning it holds 2.3x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 19.04, indicating elevated leverage, while an interest coverage ratio of -73.31 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Moderna, Inc. posted a negative return on equity (ROE) of -39.00, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -27.43, reflecting losses generated across the asset base. The company generates approximately 358,855.14 in revenue per employee across its workforce of 4,975.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 6.57 indicates how many times Moderna, Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Moderna, Inc. recorded 51.70M in income tax expense. The company reported a pretax loss of -2.49B and -2.55B in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

Over the twelve months ended June 30, 2026, Moderna, Inc. generated 1.79B in revenue and converted that into -2.55B in net income, yielding earnings per share of -6.46. EBITDA reached -2.49B, while operating income came in at -2.68B.

As of June 30, 2026, Moderna, Inc. holds 4.15B in cash and equivalents against 1.04B in total debt, resulting in a net debt position of -914.46M. Total book value stands at 5.46B, with working capital of 2.65B providing operational flexibility.

Moderna, Inc. produced -866.80M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -138.14M in capital expenditures, free cash flow totaled -1.00B - equivalent to -2.55 per share.

Over the twelve months ended June 30, 2026, Moderna, Inc. posted a gross margin of 22.76, reflecting its pricing power and cost economics. The operating margin of -150.23 and net profit margin of -142.58 provide insight into operational efficiency.